These data suggest that targeting CHEK1 exhibits a potent anticancer effect in CRC cells by attenuating cell growth, survival and stemness and promoting apoptosis and cell cycle alteration, conferring potential as a therapeutic target. This evidence concerns the gene CHEK1 and colorectal carcinoma.